Although such studies are invaluable in understanding the molecular mechanisms via which TIE1/TEK signalling may affect IOP and POAG liability, they exhibit a high false discovery rate—estimated as high as 92.6% [14]—in yielding efficacious drug targets in humans. Here, TIE1 is linked to open-angle glaucoma.